EVALUATION OF THE SAFETY AND EFFICACY OF REFORMULATED RALTEGRAVIR (MK-0518) 1200 MG ONCE DAILY IN COMBINATION WITH TRUVADA™ IN HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 INFECTED, TREATMENT-NAIVE PARTICIPANTS (MK-0518-292):